RBC Raises Price Target on Alnylam Pharmaceuticals to $300 From $265, Keeps Outperform Rating
RBC Raises Price Target on Alnylam Pharmaceuticals to $300 From $265, Keeps Outperform Rating
加拿大皇家银行将阿里拉姆制药的目标股价上调至300美元，从265美元，仍维持强于大盘的评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间